ENTEROME SA, a clinical stage biopharmaceutical company developing novel therapeutics based on its unique ability to de-code molecular interactions in the gut microbiome impacting human health, is pleased to announce the appointment of Anne Dagallier, PhD, as Chief Business Officer (CBO).
Dr Dagallier brings over 22 years of experience in global business and drug development. She joins Enterome after 19 years at Sanofi where she held several scientific and senior business development positions. Most recently, she was Head of Consumer Health Care Alliances and In-Licenses at Sanofi Global Alliances Management, where she was responsible for managing strategic alliances and in licensing deals to support Sanofi’s R&D pipeline. Dr Dagallier holds a PhD in Molecular Biophysics from University Paris 6 and an Executive MBA from Essec-Mannheim.
“We are delighted to welcome Anne to Enterome. Her extensive experience and knowledge of the industry will greatly support our efforts to progress and optimize the potential of the novel small protein and peptide candidates emerging from our unique OncoMimics and EndoMimics pipelines. We look forward to benefitting from Anne’s significant expertise as we continue to build our strong track record of successful collaborations with leading pharmaceutical and biotech companies as well as world-renowned academic institutions,” says Pierre Belichard, CEO, Enterome.
“Enterome is an exciting company, combining a unique knowledge of the gut microbiome and approach to drug development, clinical stage programs and a strong team of international industry leaders. Its approach to the microbiome has been validated through multiple collaborations. I am thrilled to join them and support the company as it advances its OncoMimics pipeline of novel targeted immunotherapies,” said Anne Dagallier.